Detalhe da pesquisa
1.
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients.
J Autoimmun
; 147: 103244, 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38797050
2.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol
; 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38284131
3.
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
J Eur Acad Dermatol Venereol
; 37(1): 93-103, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36156312
4.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Eur Acad Dermatol Venereol
; 37(5): 1017-1027, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695061
5.
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
Dermatol Ther
; 35(2): e15228, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34820969
6.
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
Dermatol Ther
; 35(2): e15253, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34877758
7.
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
Acta Derm Venereol
; 101(11): adv00605, 2021 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34596230
8.
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
J Am Acad Dermatol
; 90(5): 1031-1034, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38199282
9.
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination.
Br J Dermatol
; 189(5): 635-637, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463513
10.
Real-world data on primary cutaneous lymphoproliferative disorders following SARS-CoV-2 vaccination: A multicentre experience from tertiary referral hospitals.
J Eur Acad Dermatol Venereol
; 37(4): e451-e455, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469002
11.
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report.
Dermatol Ther
; 35(12): e15952, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36269298
12.
Cutaneous localisation of Hodgkin lymphoma resembling hard-to-heal graft-versus-host disease skin ulcers: a tricky mimic.
J Wound Care
; 31(11): 1011-1012, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36367809
13.
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report.
J Clin Immunol
; 40(7): 1038-1040, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32648026
14.
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Dermatol Ther
; 33(4): e13708, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474988
15.
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever.
Dermatol Ther
; 33(4): e13779, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32506813
16.
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.
J Pers Med
; 14(2)2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38392619
17.
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.
Dermatol Reports
; 16(1): 9722, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38623366
18.
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review.
Clin Cosmet Investig Dermatol
; 17: 593-604, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38495913
19.
Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series.
Int J STD AIDS
; 35(1): 67-70, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691387
20.
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
Dermatol Ther (Heidelb)
; 14(4): 919-932, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38509380